SPTCL : Prognosis & Treatment
Prognosis of subcutaneous panniculitis-like T-cell lymphoma (SPTCL): It is an indolent lesion with excellent prognosis. It remains confined to the subcutaneous tissues throughout its clinical course. The 5-yr disease-specific survival rate is 80-90%. If the patients develop hemophagocytic syndrome, the prognosis worsens and the 5-yr survival rate drops to around 50%. The first line treatment consists of immunomodulation therapy with steroids or cyclosporin A. Patients who develop hemophagocytic syndrome require systemic chemotherapy. This high magnification image of SPTCL shows small to medium-sized pleomorphic lymphoid cells with hyperchromatic nuclei surrounding individual adipocytes.